Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease R Zeiser, N Polverelli, R Ram, SK Hashmi, R Chakraverty, JM Middeke, ... New England Journal of Medicine 385 (3), 228-238, 2021 | 404 | 2021 |
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial M Jagasia, MA Perales, MA Schroeder, H Ali, NN Shah, YB Chen, S Fazal, ... Blood, The Journal of the American Society of Hematology 135 (20), 1739-1749, 2020 | 270 | 2020 |
Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey R Mesa, CB Miller, M Thyne, J Mangan, S Goldberger, S Fazal, X Ma, ... BMC cancer 16, 1-10, 2016 | 199 | 2016 |
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study S Verstovsek, AT Gerds, AM Vannucchi, HK Al-Ali, D Lavie, ... The Lancet 401 (10373), 269-280, 2023 | 146 | 2023 |
Supportive and palliative care of pancreatic cancer S Fazal, MW Saif Jop 8 (2), 240-253, 2007 | 109 | 2007 |
Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States … RA Mesa, CB Miller, M Thyne, J Mangan, S Goldberger, S Fazal, X Ma, ... Cancer 123 (3), 449-458, 2017 | 82 | 2017 |
Pharmacokinetic exposure equivalence and preliminary efficacy and safety from a randomized cross over phase 3 study (ASCERTAIN study) of an oral hypomethylating agent ASTX727 … G Garcia-Manero, J McCloskey, EA Griffiths, KWL Yee, AM Zeidan, ... Blood 134, 846, 2019 | 72 | 2019 |
Azacitidine in the management of patients with myelodysplastic syndromes C Khan, N Pathe, S Fazal, J Lister, JM Rossetti Therapeutic advances in hematology 3 (6), 355-373, 2012 | 72 | 2012 |
Successful plasma exchange combined with rituximab therapy in aggressive APS-related cutaneous necrosis R Costa, S Fazal, RB Kaplan, J Spero, R Costa Clinical rheumatology 32, 79-82, 2013 | 45 | 2013 |
Polycythemia AA Pillai, S Fazal, SKR Mukkamalla, HM Babiker | 38 | 2018 |
Myeloproliferative neoplasms B Thapa, S Fazal, M Parsi, HJ Rogers | 26 | 2018 |
Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised … G Garcia-Manero, J McCloskey, EA Griffiths, KWL Yee, AM Zeidan, ... The Lancet Haematology 11 (1), e15-e26, 2024 | 22 | 2024 |
Clinical efficacy and safety of oral decitabine/cedazuridine in 133 patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) MR Savona, JK McCloskey, EA Griffiths, KWL Yee, A Al-Kali, AM Zeidan, ... Blood 136, 37-38, 2020 | 22 | 2020 |
Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: a case report and literature review Y Samhouri, S Ursu, N Dutton, V Tanvi, S Fazal Journal of Oncology Pharmacy Practice 27 (4), 990-995, 2021 | 21 | 2021 |
A case of autoimmune haemolytic anaemia after 39 cycles of nivolumab H Shaikh, N Daboul, M Albrethsen, S Fazal Case Reports 2018, bcr-2018-224608, 2018 | 18 | 2018 |
Impact of myeloproliferative neoplasms (MPNs) on patients’ overall health and productivity: results from the MPN LANDMARK SURVEY in the United States R Mesa, CB Miller, M Thyne, J Mangan, S Goldberger, S Fazal, X Ma, ... Blood 124 (21), 3183, 2014 | 18 | 2014 |
Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia SK Sadashiv, C Hilton, C Khan, JM Rossetti, HL Benjamin, S Fazal, ... Cancer medicine 3 (6), 1570-1578, 2014 | 17 | 2014 |
Cerebral aspergillosis in a patient on ibrutinib therapy—A predisposition not to overlook MS Faisal, H Shaikh, A Khattab, M Albrethsen, S Fazal Journal of Oncology Pharmacy Practice 25 (6), 1486-1490, 2019 | 15 | 2019 |
Rituximab-induced acute severe thrombocytopenia: a case series in patients with mantle cell lymphoma SK Sadashiv, R Rao, S Fazal, J Lister Clinical Lymphoma Myeloma and Leukemia 13 (5), 602-605, 2013 | 15 | 2013 |
Safety and efficacy of fedratinib in patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) previously … V Gupta, A Yacoub, S Verstovsek, R Mesa, C Harrison, AM Vannucchi, ... Blood 140 (Supplement 1), 3935-3937, 2022 | 13 | 2022 |